Session R.A. II 4
4 · Taysha Gene Therapies, Inc. · Filed Dec 23, 2022
Insider Transaction Report
Form 4
Session R.A. II
DirectorPresident and CEO10% Owner
Transactions
- Award
Employee Stock Option (right to buy)
2022-11-10+199,500→ 199,500 totalExercise: $1.95Exp: 2032-11-10→ Common Stock (199,500 underlying)
Footnotes (2)
- [F1]Represents Reporting Person's annual incentive compensation for 2021 performance awarded in the discretion of the compensation committee of the Issuer's board of directors on November 10, 2022.
- [F2]25% of the total number of shares underlying the option shall vest and become exercisable on November 10, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.